Barely Significant
← all excerpts

Antiangiogeneic Strategies in Mesothelioma.

Front Oncol · 2020 · PMC7040194 · PMID 32133285

Europe PMCDOI
1
hedged sentence
0.3200
closest p · 6.4× alpha
0.3200
boldest claim

The sentences

showed a trendP = 0.32not close (p > 0.1)
Although underpowered, OS also showed a trend to benefit with addition of nintedanib (HR, 0.77; 95% CI, 0.46–1.29; P = 0.32).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.